- Home
- MOLN
as 12-18-2024 12:39pm EST
Stocks
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
| Founded: | 2004 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 214.4M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 26.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.32 - $12.70 | Next Earning Date: | 08-26-2024 |
| Revenue: | $7,105,397 | Revenue Growth: | -31.03% |
| Revenue Growth (this year): | -17.87% | Revenue Growth (next year): | 29.41% |
Latest Molecular Partners AG News
MOLN Breaking Stock News: Dive into MOLN Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 hours ago
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
Zacks
5 days ago
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet
GlobeNewswire
10 days ago
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
GlobeNewswire
a month ago
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
GlobeNewswire
a month ago
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
GlobeNewswire
2 months ago
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
GlobeNewswire
2 months ago
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
TipRanks
2 months ago
Molecular Partners Expands Radio-DARPin Collaboration
Compare MOLN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MOLN Molecular Partners AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.